Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Steroid trial for COVID brain fog halted early

NCT ID NCT05986422

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the steroid methylprednisolone could improve memory and thinking in people with long COVID. About 96 adults with ongoing memory problems were to receive either the drug or a placebo for six weeks. The trial was terminated early, so we don't know if the treatment works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylprednisolone (a steroid that reduces inflammation)
What this could lead to
If it had worked, this could point toward a treatment for memory problems after COVID-19.
What could go wrong
The trial was terminated early, so we don't have clear results. Steroids like methylprednisolone can have side effects, and it's unknown if they help brain fog.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

96 people

The number who actually took part.

Started

Oct 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of confirmed (PCR or serology) SARS-CoV-2 infection according to WHO criteria * Ongoing symptoms of PCS for ≥ 3 months * Self-reported cognitive deficits at screening * Male or female adult who is 18 years or older at the time of informed consent * Subject is willing, understanding and able to provide informed consent * Signed informed consent prior to initiation of any trial related measure * For female subject or divers subjects: 1. Confirmed post-menopausal state, defined as amenorrhea for at least 12 months, or 2. If being of childbearing potential: 1. Negative highly sensitive urine or serum pregnancy test before inclusion, and 2. Practicing a highly effective birth control method (failure rate of less than 1%) Exclusion Criteria: * Any ongoing central nervous system disease * Any major psychiatric disease within the last 10 years * Previous medical history of gastric ulcer, osteoporosis and/or previous vertebral fractures, rheumatological disease or metabolic disease including diabetes mellitus * Ongoing immunosuppressive therapy * Patient is pregnant or breastfeeding at screening * MMQ memory satisfaction subdomain \>50 points at Screening * Current malignant disease (including space-occupying brain tumors) * Body weight \<45kg * Severe lactose intolerance * Participation in another clinical interventional trial within the last 3 months or five half- lives of the other trial's IMP, if longer than 6 months previous to informed consent * Patient is institutionalized by order of court or public authority * Patient who might be dependent on the sponsor, the investigator or the trial site * Place of living does not allow the subject to attend the planned study visits * Other conditions that are likely to affect to safety of the study treatment (e.g., severely impaired immune status)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-COVID-19 syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.